Literature DB >> 11869952

Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON).

Arturo Muñoz, Isabel Badell, Teresa Olivé, Amparo Verdeguer, Pedro Gómez, Encarna Bureo.   

Abstract

Twenty-four children with acute leukemia (21) or chronic myeloid leukemia (3) who relapsed after a first hematopoietic stem cell transplantation (HSCT) underwent a second allogeneic HSCT. Sixteen patients died from relapse or transplant related causes and 8 are alive and disease-free with a probability of event-free survival at 5 years of 32%. These results show that this procedure offers a chance to a subset of these patients.

Entities:  

Mesh：

Year:  2002        PMID： 11869952

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  5 in total

1.  Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.

Authors:  Ashok Srinivasan; John C Panetta; Shane J Cross; Asha Pillai; Brandon M Triplett; David R Shook; Mari H Dallas; Christine Hartford; Anusha Sunkara; Guolian Kang; Jeffrey Jacobsen; John Choi; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-23       Impact factor: 5.742

2.  Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.

Authors:  R Vrhovac; M Labopin; F Ciceri; J Finke; E Holler; J Tischer; B Lioure; J Gribben; L Kanz; D Blaise; P Dreger; G Held; R Arnold; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

3.  Effects of second transplantation with T-cell-replete haploidentical graft using low-dose anti-thymocyte globulin on long-term overall survival in pediatric patients with relapse of leukemia after first allogeneic transplantation.

Authors:  Shogo Kobayashi; Hideki Sano; Kazuhiro Mochizuki; Yoshihiro Ohara; Nobuhisa Takahashi; Shingo Kudo; Kazuhiko Ikeda; Hitoshi Ohto; Atsushi Kikuta
Journal:  Int J Hematol       Date:  2021-11-25       Impact factor: 2.490

4.  Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms.

Authors:  Akshay Sharma; Guolian Kang; Anusha Sunkara; Hiroto Inaba; Sima Jeha; Shane J Cross; Terrence Geiger; Brandon Triplett
Journal:  J Pediatr Hematol Oncol       Date:  2018-11       Impact factor: 1.289

5.  Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.

Authors:  Ursula Jördis Eva Seidel; Patrick Schlegel; Ludger Grosse-Hovest; Martin Hofmann; Steffen Aulwurm; Elwira Pyz; Friedhelm R Schuster; Roland Meisel; Martin Ebinger; Tobias Feuchtinger; Heiko-Manuel Teltschik; Kai-Erik Witte; Carl-Philipp Schwarze; Hans-Georg Rammensee; Rupert Handgretinger; Gundram Jung; Peter Lang
Journal:  Mol Ther       Date:  2016-07-06       Impact factor: 11.454
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.